XML 34 R24.htm IDEA: XBRL DOCUMENT v3.25.1

Collaboration, License, and Other Agreements (Tables)

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Collaborative Revenue

Net product sales consist of the following:

									Three Months Ended March 31,
(In millions)									2025						2024
EYLEA HD®			U.S.						$	306.8					$	200.0
EYLEA®			U.S.						736.0						1,201.6
Total EYLEA HD and EYLEA			U.S.						1,042.8						1,401.6
Libtayo®			U.S.						192.5						159.2
Libtayo			Rest of world						92.6						104.7
Total Libtayo			Global						285.1						263.9
Praluent®			U.S.						56.8						70.0
Evkeeza®			U.S.						30.9						24.8
Inmazeb®			Rest of world						—						1.0
									$	1,415.6					$	1,761.3

Amounts recognized in the Company's Statements of Operations in connection with its Sanofi collaboration are as follows:

						Statement of Operations Classification						Three Months Ended March 31,
(In millions)												2025						2024
Regeneron's share of profits						Collaboration revenue						$	1,018.2					$	804.0
Reimbursement for manufacturing of commercial supplies						Collaboration revenue						$	165.0					$	105.8
Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses						(R&D expense)						$	(15.5)					$	(18.6)
Reimbursement of commercialization-related expenses						Reduction of SG&A expense						$	159.2					$	139.5

Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:

						Statement of Operations Classification						Three Months Ended March 31,
(In millions)												2025						2024
Regeneron's share of profits						Collaboration revenue						$	317.3					$	333.9
Reimbursement for manufacturing of commercial supplies						Collaboration revenue						$	26.6					$	22.1
Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses						(R&D expense)						$	(9.4)					$	(8.7)

Schedule of Accounts Receivable and Deferred Revenue Information

The following table summarizes contract balances in connection with the Company's Sanofi collaboration:

						March 31,						December 31,
(In millions)						2025						2024
Accounts receivable, net						$	1,192.8					$	1,216.2
Deferred revenue						$	549.5					$	571.7

The following table summarizes contract balances in connection with the Company's Bayer collaboration:

						March 31,						December 31,
(In millions)						2025						2024
Accounts receivable, net						$	373.2					$	349.9
Deferred revenue						$	260.0					$	216.3

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration